Pharma 101 - Pharmaceutical Fraud
InterMune Pays Nearly $37 Million to Settle Claims for Off Label Marketing
InterMune Inc., a Brisbane, California, biopharmaceutical company, has agreed to pay the government $36.9 million to resolve criminal charges and civil liabilities in connection with allegations of illegally promoting Actimmune for treatment of idiopathic pulmonary fibrosis (IPF) or lung scarring despite not receiving approval for such treatment by the U.S. Food and Drug Administration. This settlement resolves allegations that InterMune caused the submission of false claims for Actimmune that were not eligible for reimbursement because they were for unnecessary or off label uses. The FDA had approved Actimmune for treating immune system disorders.
For more information please click here.
No Tags| Posted By Marcella Auerbach | |
| Category Legal | Posted October 30th, 2006 |
| Bookmark | |
Leave a Reply
Regulatory Documents (PDF)
- OIG Compliance Program Guidance for Pharmaceutical Manufacturers
- Medicaid Rebate Applicability of Physician Administered Drugs
Nolan Law Firm Articles
- Pages
- Categories
- Clinical Trials (2)
- Legal (36)
- Medicare (4)
- Off-Label (2)
- Pharmaceutical (2)
- Feeds
- Archives
Nolan & Auerbach, P.A. is a qui tam law firm whose practice is uniquely limited to healthcare fraud cases under the qui tam provisions of the False Claims Act. We know healthcare fraud because that's what we do! Toll free: 800-FRAUD 04
"The hiring of a lawyer is an important decision that should not be based
solely on advertisements. Before you decide, ask us to send you free written
information about our qualifications and experience."
Licensed in Florida
Located in Fort Lauderdale, Florida
Available for National Cases